Trials / Completed
CompletedNCT05176873
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a study in healthy adult participants. This is the first time this drug has ever been tested in human, and so it will help to understand what type of side effects may occur with this intervention. It will also measure the levels of drug in the body.
Detailed description
This is a study in healthy adult participants. This is the first time this drug has ever been tested in human, and so it will help to understand what type of side effects may occur with this intervention. It will also measure the levels of drug in the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DZD8586 | Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586. |
| DRUG | Placebo | A single oral dose of placebo will be given. |
Timeline
- Start date
- 2021-12-09
- Primary completion
- 2022-05-11
- Completion
- 2022-05-22
- First posted
- 2022-01-04
- Last updated
- 2023-09-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05176873. Inclusion in this directory is not an endorsement.